Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

Phase 2

Not yet recruiting

• Conditions: Pancreatic Cancer, Advanced or Metastatic; BRCA1/2 Mutation; PALB2 Gene Mutation
• Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin

• Registration Number: NCT06783140
• Lead Sponsor: University Health Network, Toronto

Brief Summary

This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-01-16
• Study First Submitted QC: 2025-01-16
• Study First Posted: 2025-01-20
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-11
• Last Update Posted: 2025-04-15
• Study Start: 2025-06-02
• Primary Completion: 2031-06-02
• Study Completion: 2031-06-02

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Metastatic pancreatic adenocarcinoma. Adenosquamous carcinoma, squamous carcinoma, acinar cell carcinoma, and carcinoma not otherwise specified are also acceptable.

• BRCA1/2 or PALB2 mutation (somatic or germline).

• Measurable disease.

• Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment.

• Clinical or radiographic progression on first-line FOLFIRINOX (or NALIRIFOX) for metastatic disease.

  • Patients whose front-line chemotherapy was required to be simplified due to toxicity associated with any of the constituent components of FOLFIRINOX/NALIRIFOX (e.g. simplified to FOLFOX, FOLFIRI, 5-FU (including capecitabine)) will be eligible.
  • Patients with progressive disease while on maintenance PARP inhibitor treatment after FOLFIRINOX (or NALIRIFOX), irrespective of how long ago they received FOLFIRINOX/NALIRIFOX, will also be eligible.
  • Patients who develop metastatic disease during or within 6 months after completing FOLFIRINOX/NALIRIFOX in either the locally advanced or adjuvant/neoadjuvant settings will be eligible.

• Age 18 years or older.

• Ability to understand and willing to sign a written informed consent document.

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Karnofsky Performance Status ≥60).

• Required Initial Laboratory Values

• Not pregnant and not nursing.

Exclusion Criteria

• Patients may not have received prior cisplatin for their pancreatic cancer in any setting.
• Patients with > grade 2 peripheral sensory neuropathy are not eligible.
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for at least 8-weeks. Patients with known, new or progressive brain metastases (active brain metastases) or leptomeningeal disease are ineligible.
• HIV-infected patients on effective anti-retroviral therapy with undetectable viral load anytime within 6 months prior to registration are eligible for this trial.
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Concomitant Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study. Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1- NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine)	Nab paclitaxel	Nab-paclitaxel 100 mg/m2 + cisplatin 25 mg/m2 + gemcitabine 800 mg/m2 on days 1 and 15 of every cycle.
Arm 1- NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine)	Gemcitabine	Nab-paclitaxel 100 mg/m2 + cisplatin 25 mg/m2 + gemcitabine 800 mg/m2 on days 1 and 15 of every cycle.
Arm 1- NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine)	Cisplatin	Nab-paclitaxel 100 mg/m2 + cisplatin 25 mg/m2 + gemcitabine 800 mg/m2 on days 1 and 15 of every cycle.
Arm 2 - Nab-paclitaxel+gemcitabine	Nab paclitaxel	Nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 on days 1 and 15 of every cycle.
Arm 2 - Nab-paclitaxel+gemcitabine	Gemcitabine	Nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 on days 1 and 15 of every cycle.

Primary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR)	12 months	The proportion of patients who achieve complete response (CR) or partial response (PR)
Overall Survival (OS) Time	6 years	The time form the date of randomization to the date of death

Secondary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS)	6 years	Time from the date of randomization to the date of first documented disease progression or death
Duration of Response (DoR)	6 years	The time that criteria are met for complete response (CR) or partial response (PR) until the first date that recurrence or disease progression is objectively documented.
CA19-9 Response	6 years	Percentage decrease in CA19-9
Number of Adverse Events	6 years

Trial Locations

Locations (1)

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada